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Abstract
Background: The major pathological type of non-small cell lung cancer is lung adenocarcinoma (LAC), which has a
poor prognosis. BRCA1-associated protein-1 (BAP1) is a newly identified tumor suppressor that regulates a number
of cellular functions in somatic malignancies. However, the impact of BAP1 expression in LAC has not been
investigated.
Methods: A total of 112 cases of LAC and 101 cases of non-neoplastic lung diseases were included in this study.
The study focused on BAP1 expression in lung tissues and its relationship to patients’ clinical and pathological
features. BAP1 expression was detected by immunohistochemistry. A human LAC cell line NCI-H1299 was transfected
with lipofectamine p3xFLAG-BAP1. BAP1 gene expression was silenced in another LAC cell line NCI-H1650, in order to
test the inhibitory effect of BAP1 on cell migration and invasion, as well as cell cycle regulation.
Results: BAP1 expression showed a negative correlation with tumorigenesis of LAC (p <0.001) and lymph node
metastasis (p = 0.010). High expression of BAP1 predicted longer disease free survival (p = 0.040) and overall
survival (p = 0.021) of LAC patients. In functional assays, BAP1 was found to inhibit the migration and invasion
of LAC cells, and promoted their apoptosis and necrosis.
Conclusions: We identify BAP1 as a LAC precursor as well as a robust prognostic indicator in LAC patients.
This study provides in vitro rationale for the further investigation of BAP1 in preclinical studies.
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Background
Lung cancer is the most common cause of cancer-
related death with an annual mortality rate of 18 %
worldwide [1]. Non-small cell lung cancer (NSCLC) pre-
sents with advanced pathologic features and has a poor
prognosis. Lung adenocarcinoma (LAC) is currently the
predominant histological subtype of NSCLC [2] with an
average 5-year survival rate of 15 % despite using epider-
mal growth factor receptor (EGFR)-targeted therapies.
This poor outcome is due in a large part to the delay in
diagnosis in the early stages and a paucity of treatments
against lymph node metastasis [3, 4]. Evidence also sug-
gests that genetic susceptibility also contributes to ma-
lignancy risk in LAC [5].
Ubiquitin proteasome system (UPS) is involved in
intracellular protein degradation, playing a crucial role
in physiological processes including cell proliferation,
apoptosis and migration [6, 7]. Deubiquitination en-
zymes (DUBs) act as hydrolases, catalyzing the reverse
reaction of ubiquitination [8, 9]. So far, six subfamilies of
DUBs have been found: the ubiquitin C-terminal hydro-
lases (UCHs), the ubiquitin-specific proteases (USPs/
UBPs), the ovarian tumor proteases (OTUs), the
Machado-Joseph disease protein domain proteases
(MJDs), the Jab1/MPN domain-associated metalloiso-
peptidase (JAMM) domain proteins and the monocyte
chemotactic protein-induced protein (MCPIP) [9, 10].
* Correspondence: dx2008cn@163.com
Chen Shen and Yiqin Wang shared the first-authorship.
†Equal contributors
1Department of Pathology, Fudan University Shanghai Cancer Center,
Shanghai 200032, China
2Department of Oncology, Shanghai Medical College, Fudan University,
Shanghai 200032, China
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shen et al. BMC Cancer  (2016) 16:670 
DOI 10.1186/s12885-016-2670-x
BRCA1-associated protein-1 (BAP1), is a 729aa
protein and UCH family member, which exerts its
DUB function via binding to the RING finger domain
of BRCA1 thereby inhibiting its self-ubiquitination
[11, 12]. Accumulating evidence has implicated BAP1
as a tumor suppressor since frequent loss of hetero-
zygosity, large rearrangements, deletions and mis-
sense mutations of the BAP1 gene have been found
in breast tumors and lung cancer [13, 14]. Evidence
has indicated that both DUB enzyme activity and nu-
clear localization are necessary conditions for its
tumor suppressor activity [15, 16]. In functional exper-
iments, BAP1 has been shown to suppress lung cancer
tumorigenesis in athymic nude mice, promote the cell
cycle and induce both apoptosis and necrosis. Moreover,
BAP1-mediated regulation of cell growth is independent
of wild-type BRCA1 [16]. In contrast, there is little re-
search paper exploring the effect of BAP1 on tumor me-
tastasis, particularly in lung cancer [17]. Recent research
has suggested that BAP1 may be a prognostic factor in ad-
vanced NSCLC although this has not been thoroughly in-
vestigated [12].
In the present study we show that the deficiency in
BAP1 expression is a strong predictor of malignant
transformation of LAC cells. We also report a positive
correlation between BAP1 and patient outcome and pro-
vide evidence that BAP1 overexpression promotes mi-
gration and invasion of adenocarcinoma.
Methods
Patients and tissue samples
A total of 112 cases of LAC and 101 cases of non-
neoplastic lung diseases were collected in Fudan
University Shanghai Cancer Center (Shanghai, China)
from 2007 to 2011. Non-neoplastic lung diseases in-
clude a wide range of pathologic disorders from scler-
osing hamartoma, pulmonary tuberculosis, pneumonia
to bronchiectasis. Among the 112 cases of LAC, 59
were male and 53 were female, with an age range of
33 to 79 years (mean 57.6). Twelve out of 112 LAC
cases were diagnosed as well-differentiated adenocar-
cinoma, 82 as showing moderate differentiation and
the remaining 19 cases as poorly differentiated. Ac-
cording to the Union for International Cancer Con-
trol’s TNM staging criteria (2009), 58 patients were
considered pathologic stage I or II and 54 with stage
III, with no patient with stage IV undergoing surgery.
The inclusion criteria were as follows: (a) LAC was
confirmed by surgery and pathology; (b) use of bron-
choscope specimens was excluded; (c) preoperative
chemotherapy or radiotherapy was not received; (d)
similar postoperative chemotherapy regimens were
conducted. The median follow-up period for all
patients was 25 months. Written informed consent
was obtained from each patient.
Immunohistochemistry
BAP1 immunohistochemical (IHC) staining was per-
formed on all 213 surgical specimens from patients
who were treated by pneumonectomy, lobectomy or
wedge resection of lung. Formalin-fixed and paraffin-
embedded tissues for IHC were dewaxed in xylene
and dehydrated in ethanol. Sections were cut at 4-μm
thickness, and then rinsed in 0.05 mol/L phosphate
buffer solution (PBS) and incubated overnight at 4 °C
with anti-BAP1 antibodies (1:200, HPA028814, Sigma,
St. Louis, USA). We also employed 3 % hydrogen
peroxide for the inhibition of endogenous peroxidase
activity. Steps were performed using DAB horseradish
peroxidase color development Kit (Sangon Biotech,
Shanghai, China) according to the manufacturer’s in-
structions. We mixed slides of non-neoplastic disease
and slides of LAC tissues so that in each batch of
assay there were slides from both groups acting as
positive and negative controls.
Brown nuclear staining of LAC cells or bronchial
epithelial cells is considered positive. Evaluation of
IHC staining was conducted on anonymized slides by
two independent pathologists by light microscopy
(Olympus Corp. BX-50). The labels of slides were
carefully covered up so that none of the observers was
able to make sure about the patient health informa-
tion. Intensity of positive immunostaining was graded
as low expression (<30) and high expression (≥30 %)
[12] using 30 % as a cut-off point. To model on this
method, I presuppose 10 as cut-off point and divide
all patients into two groups, less than 10 positive and
more than 10 % positive. Then, draw a survive curve
of each group, calculate the p10 % value between the
two groups. Second, I presuppose 20 % as cut-off
point, divide all patients into two groups and calculate
the p20 % value between them, and so forth. Then I
get the value of p10 %, p20 %, p30 %, up to p90 %.
Choose the minimum p value from the former nine
numbers, so that the percentage is the ideal cut-off
point. Therefore we instead use 30 % as cut-off point
according to the literature. Images were captured from
an Olympus Corp. Oly 760 video camera.
Cell culture
The human LAC cell lines NCI-H1650, NCI-H1299,
SPCA-1 and large cell lung cancer cell line NCI-H460
were purchased from American Type Culture Collection.
Cells were initially maintained in RPMI-1640 medium
(Gibco, U.S.A.), supplemented with 10 fetal bovine
serum and 1 % penicillin and streptomycin, incubated at
37 °C in a humidified atmosphere containing 5 % CO2.
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Gene silencing, plasmid DNA construction and
transfection
We measured the level of BAP1 background expression
in the four lung cancer cell lines mentioned above by
western blot. H460 was excluded because it originates in
large cell undifferentiated carcinoma. The work on gene
silencing was performed on H1650, which overexpresses
the BAP1 protein, to obtain an artificial LAC cell line
that expresses extremely low levels of BAP1. Meanwhile,
we transfected the cell line H1299, which expressed the
lowest level of background BAP1, with plasmid DNA to
generate a cell line with artificially high expression of
BAP1.
We used Lipofectamine 2000 (Invitrogen) for transfec-
tion of both siRNA and plasmid DNA, according to the
manufacturer’s instructions. Transient knockdown was
carried out with 100 nmol/L BAP1 siRNA or negative
control (NC) siRNA (GenePharma, Shanghai, China) in
H1650 as previously described. The effect of transient
knockdown was proved lasting no less than 72 hours.
(Fig. 1) We ordered three siRNA oligos of different se-
quence, all of whom showed an effective in silencing
BAP1 expression in different extent, and selected the
most efficient as assessed by RT-PCR (Fig. 2 and Table 1).
H1650 cells (2.5 × 105) were seeded into 6-well plates
and incubated overnight, after which double-stranded
siRNAs were transfected into cells. RNA or protein ex-
traction was performed within 72 h. The sequences of
NC siRNA pairs were: 5′-UUCUCCGAACGUGUCAC
GUTT-3′ (sense), and 5'-ACGUGACACGUUCGGA
GAATT-3' (anti-sense). Sequences of BAP1 siRNA pairs
were: 5'-GGCUGAGAUUGCAAACUAUTT-3' (sense),
and 5'-AUAGUUUGCAAUCUCAGCCTT-3' (anti-sense).
Full-length human BAP1 cDNA (GenBank accession
number: NM_004656.3) was generated and cloned by
polymerase chain reaction (PCR). The p3xFLAG-BAP1
vector was purchased from Bioworld Technology, Inc.
(Shanghai, China). The amplified cDNA was sequenced to
ensure there were no missense mutations. H1299 was
then transfected with recombinant vectors.
Fig. 1 Confirmation of expression of BAP1 and cell cycle and
growth-related proteins by Western blotting within 72 h
Fig. 2 At the beginning, 3 si oligos of different sequence were ordered.
The sequences are listed as Table 4. Then the silence effects of BAP1-
siRNAs in H1650 cells were tested by Rt-PCR. Relative amount of BAP1-
mRNA decreased to 49 (0.49 ± 0.21), 32 (0.32 ± 0.07) and 10 % (0.10 ±
0.03). The best silencing effect was interfered by BAP1-homo-2145. So
we used si oligos of this sequence in the subsequent experiments
Table 1 Sequences of 3 si oligos
siRNA serial Sequence and antisense sequence
BAP1-homo-1298
Sense (5′–3′) CGG CCU UUC UAG ACA AUC ATT
Antisense (5′–3′) UGA UUG UCU AGA AAG GCC GTT
BAP1-homo-2143
Sense (5′–3′) GAG GCU GAG AUU GCA AAC UTT
Antisense (5′–3′) AGU UUG CAA UCU CAG CCU CTT
BAP1-homo-2145
Sense (5′–3′) GGC UGA GAU UGC AAA CUA UTT
Antisense (5′–3′) AUA GUU UGC AAU CUC AGC CTT
Negative control (scramble RNA)
Sense (5′–3′) UUC UCC GAA CGU GUC ACG UTT
Antisense (5′–3′) ACG UGA CAC GUU CGG AGA ATT
Positive control (GAPDH)
Sense (5′–3′) GUA UGA CAA CAG CCU CAA GTT
Antisense (5′–3′) CUU GAG GCU GUU GUC AUA CTT
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RNA extraction and RT-qPCR
Total RNA was extracted from cultured LAC cells using
TRIzol from Invitrogen. Quantitative analysis of BAP1
mRNA expression was performed by RT-qPCR and re-
peated three times for each batch. Primes for BAP1
RNA amplification were 5'-ATGAATAAGGGCTGGCT
GGAGCTG-3' (forward) and 5'-GGGTATCAGCTGG
TGGGCAAAGAA-3' (reverse). Thermal cycling condi-
tions were as follows: one cycle of 95 °C for 5 min; 40 cy-
cles for 95 °C for 20 s, 58 °C for 30 s, and 68 °C for 45 s;
and one cycle of 72 °C for 10 min. The specificity of the
PCR amplification was validated by a single peak in the
melting curve.
Western blot analysis
Total protein samples, lysed from cells using RIPA lysis
buffer (Abcam), were separated using 10 % SDS-PAGE
gel electrophoresis and then transferred onto a nitrocel-
lulose membrane. The membrane was blocked with 5 %
(w/v) Bovine serum albumin (BSA) in TBST (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.1 % Tween-20), and
incubated with primary antibody at 4 °C overnight
followed by horseradish peroxidase-conjugated second-
ary antibody in 5 % BSA-TBST the next day for 2 h at
room temperature. The immunoreactive bands were vi-
sualized using enhanced chemiluminescence with ECL
luminescence (Thermo Scientific, Hudson, NH, USA).
Primary antibodies used were anti-GAPDH (#5632–1,
Epitomics, Burlingame, CA, USA) as a loading control,
anti-cyclinB1 (#4135, Cell Signaling, Boston, Massachusetts,
USA), anti-P27 (kip1, #PA5–17830, Lab Vision Corpor-
ation, Fremont, CA) and anti-PARP-1 (#ab32138, Abcam,
Massachusetts, USA).
Cell proliferation assays
The proliferation of H1650 and H1299 cells trans-
fected with siRNA or p3xFLAG-BAP1 was indirectly
assayed using the Cell Counting Kit-8 (CCK-8,
Dojindo, Japan), which quantifies cell viability. One
hundred microliters of transfected cells (approxi-
mately 5 × 103) were then plated into each well of a
96-well plate. At 24 h, 48 h, and 72 h, 10 μl of CCK-
8 reagent was added to each well, and the cells were
incubated at 37 °C for 2 h. The optical density (OD)
Fig. 3 Immunohistochemical staining patterns of BRCA1-associated protein (BAP1) in lung adenocarcinoma. The upper two pictures (a, b) show
low expression of BAP1 while the lower two (c, d) show high expression of BAP1. The cut-off point was 30 %. Scale bars are showed at the bottom
right corner of each graph. Magnification is × 100 (a, c), and × 400 (b, d)
Table 2 Correlation between BAP1 expression and oncogenesis
Tissue BAP1 expression P value
Lowa Highb
Non-neoplastic 10 91 <0.001
Malignant 80 32
a < 30 % bronchial epithelial cells or tumor cells were positive stained
b ≥ 30 % bronchial epithelial cells or tumor cells were positive stained
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Table 3 Correlation between BAP1 expression and clinicopathologic parameters of lung adenocarcinoma
Clinicopathological features n % BAP1 Expression P value
Low High
All cases 112 100 80 32
Sex Male 59 52.68 45 14 0.231
Female 53 47.32 35 18
Age (years)
(Average 57.6)
<60 66 58.93 50 16 0.224
≥60 46 41.07 30 16
Gross Type Central 82 73.21 59 23 0.840
Peripheral 30 26.79 21 9
Diameter of Tumor (cm)
(Average 3.67)
<3.0 37 33.04 26 11 0.849
≥3.0 75 66.96 54 21
Differentiation Well 12 10.71 7 5 0.458
Moderate 82 73.21 61 21
Poor 18 16.07 12 6
Tumor Status T1, T2 97 86.61 66 31 0.044
T3, T4 15 13.39 14 1
pTNM Stage I, II 58 51.79 35 23 0.007
III 54 48.21 45 9
Node Status N0, N1 59 52.68 36 23 0.010
N2, N3 53 47.32 44 9
Pleural Invasion (−) 43 38.39 24 19 0.004
(+) 69 61.61 56 13
Post-operative relapse or metastasis (−) 45 40.18 27 18 0.0028
(+) 67 59.82 53 14
P value, below 0.05 threshold, is in bold
Fig. 4 Correlation between BAP1 expression and disease free survival/Overall Survival FS/OS. Curve (a) shows that BAP1 expression was
significantly associated with disease free survival (p = 0.040). And curve (b) shows that BAP1 predicts a longer overall survival in lung
adenocarcinoma (LAC) (p = 0.021)
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at 450 nm was measured using an automatic micro-
plate reader (Synergy4; BioTek, Winooski, VT, USA).
For the cell cycle assay, cells were seeded in 6-well
plates (2.5 × 105 cells per well) and harvested after 24 h
of treatment with blank vector or plasmid DNA,
followed by 12 h cultivation in serum-free medium. Cell
cycle distribution was determined by flow cytometry
using FACS Calibur (Becton-Dickinson and Company,
Franklin Lakes, NJ, USA) with propidium iodide (PI)
and analyzed using CELL Quest software (Becton Dick-
inson and Company, CA, US.).
Apoptosis was assessed using the Annexin V-FITC
apoptosis detection kit I and FITC-conjugated antibody
was purchased from the Beyotime Institute of Biotech-
nology (Shanghai, China). Cells were seeded in 6-well
plates, incubated with doxorubicin (1 μl per well) for
16 h, and harvested as previously described. DNA con-
tent was measured after 30 min of staining with PI. Fi-
nally, the cells were analyzed with a flow cytometer
using an Epics system (Coulter Epics XL) equipped with
an argon ion laser operated at a wavelength of 488 nm.
Surface exposure of phosphatidylserine in apoptotic cells
was measured using the Annexin V-FITC/PI apoptosis
detection kit I.
Wound healing assay and Transwell assay
For the wound healing assay, H1650 cells and H1299
cells were grown until 70 % confluent in 6-well
plates. Then H1650 cells were transfected with siNC
or siBAP1, while H1299 cells were treated with blank
vector or p3xFLAG-BAP1 overnight. Cells were
scraped off using a pipette tip and washed with PBS
twice to remove floating cells and debris. Representa-
tive images of cells migrating into the wounds were
captured at 0 h, 24 h and 48 h in the same wounded
region.
For cell invasion assays, Transwell inserts with an
8-μm pore size for 24-well plates were pre-coated
with Matrigel (ECM550, Chemicon). Transfected cells
were seeded in the upper chamber (8 × 104 cells per
well) in RPMI 1640 serum-free medium. Medium
with 20 % FBS was added in the bottom chamber.
After 24 h (for H1299 cells) or 48 h (for H1650
cells), the cells on the upper surface of the filter were
removed by wiping with a cotton swab, and the inva-
sive cells that penetrated through the Matrigel were
counted in 20 random grids under an inverted micro-
scope (40×).
Statistical analysis
The statistical significance of the correlation between
expression of BAP1 and several clinicopathological
parameters was assessed by the chi-squared (χ2) test,
as was the correlation between BAP1 expression and
malignant status. The probability of cumulative over-
all survival (OS) and disease free survival (DFS) as a
function of time was estimated by the Kaplan–Meier
method and the log-rank test. Multivariate survival
analysis was performed using the Cox regression
Table 4 Multivariate Cox regression model for lung
adenocarcinoma patients’ survival
Characteristics P value SE Exp(B) 95 % CI for Exp(B)
BAP1 expression 0.185 0.578 0.465 0.150–1.444
Pleural Invasion 0.048 0.479 2.584 1.010–6.608
Differentiation 0.003 0.365 2.930 1.433–5.990
TNM Stage 0.027 0.383 2.329 1.099–4.935
P value, below 0.05 threshold, is in bold
Fig. 5 a Background expression of BAP1 in lung cancer cell lines.
LAC cell lines H1650 and H460 expressed a high background BAP1,
therefore one of these (H1650) was chosen for gene knockdown
experiments. H1299 expressed the lowest BAP1, so was chosen for
BAP1 overexpression experiments by plasmid transfection. Transfection
efficiencies were detected by immunoblotting. b and Rt-PCR (c). MW is
marked in red under the bands
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Fig. 6 Expression of BAP1 and cell cycle-related proteins. P27 was inversely influenced by BAP1 while CyclinB1 expression changed in accordance
with BAP1. It is widely accepted that the expression of P27 is down-regulated when the cell cycle runs slower. MW is marked in red under
the bands
Fig. 7 Wound-healing assay. From a baseline taken at 0 h, we measured the gap between the cells at 24 h and 48 h, which were recorded as
percentages ± standard deviation. Width of the gap was compared with the control group, and compared by paired t test. *p < 0.05
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model. P values less than 0.05 were considered as sta-
tistically significant. SPSS (version 18.0, SPSS, Inc.,
Chicago, IL) was used for statistical evaluation. Histo-
grams were constructed by Graphpad prism 5. The
MW value was detected by ImageJ (Ver 1.48). The
comparison of the two groups in the Transwell assay
and RT-qPCR was verified by a t test.
Results
BAP1 expression in lung adenocarcinoma and
clinicopathologic findings
To investigate the potential role of BAP1 in the gen-
eration and progression of LAC, we performed im-
munohistochemical staining on samples from 112
cases of LAC and 101 cases of non-neoplastic lung
diseases. BAP1 straining was strongly positive in 91
of the 101 non-neoplastic cases (90.1 %), significantly
higher than the rate of high expression in LAC (32
out of 112 cases, 28.6 %; p < 0.01), suggesting a defi-
ciency of BAP1 expression in LAC tissues (Fig. 3 and
Table 2).
Next we conducted a statistical analysis to explore
the correlation between BAP1 expression and the
clinicopathologic characteristic of LAC patients. Ex-
pression of BAP1 was closely related to tumor status
(p = 0.044), pTNM stage (p = 0.007), node status (p =
0.010), pleural invasion (p = 0.004) and post-operation
relapse or metastasis (p = 0.0028) (Table 3). However,
there was no significant association between BAP1
expression and other clinicopathologic features, in-
cluding patient sex, age, gross type, diameter of
tumor in the greatest dimension, and degree of histo-
logical differentiation.
Survival analysis
To determine the association between BAP1 expres-
sion and patient outcome as measured by OS and
DFS, we performed Kaplan–Meier analysis and log-
rank test after 25 months of follow-up. As shown
in Fig. 4, higher expression of BAP1 in LAC pre-
dicted a higher OS rate and DFS rate (p = 0.040 and
p = 0.021, respectively). A subsequent multivariate
survival analysis of prognostic factors again demon-
strated that higher expression of BAP1 was an inde-
pendent prognostic factor in LAC, significantly
associated with a longer life expectancy (Fig. 4 and
Table 4). Notably, pTNM stage, another independent
prognostic factor of LAC, also showed a significant
association with BAP1 expression (Tables 3 and 4),
suggesting that high expression of BAP1 strongly
predicts longer survival and better prognosis in
LAC.
Fig. 8 Transwell assay. The upper two graphs (a, b) shows cells that
passed through Matrigel into the lower chamber. Magnification is ×
100 (left), and × 400 (right). The average number of H1650 siNC cells
that passed through Matrigel was 59.53 per field of view at high
magnification, compared with 91.56 in H1650 siBAP1 (p < 0.01) a.
The average number of H1299 vector cells that passed through
Matrigel was 129.8 per FOV at high magnification, compared with
64.62 in H1299 cells overexpressing BAP1 (p < 0.01) b. The lower bar
chart shows the number of invaded cells assessed by t test (c)
Shen et al. BMC Cancer  (2016) 16:670 Page 8 of 13
BAP1 inhibits migration and invasion abilities of cells in
vitro
Based on the findings above, we hypothesized that
BAP1 might function as an invasion suppressor pro-
tein in cells. We therefore constructed a p3xFLAG-
BAP1 plasmid and siRNAs and evaluated their effi-
ciency on lung cancer cell lines. An immunoblotting
assay (IB) was adapted to detect baseline expression
of BAP1 in four lung cancer cell lines, H1299,
H1650, H1299 and H1650, to determine the best
lines for subsequent functional experiments. H1299
cells showed the lowest level of BAP1 and H1650
cells showed the highest expression (Fig. 5). These
were therefore selected for BAP1 enhancement and
knockdown, respectively. H1299 cells were trans-
fected with plasmid p3xFLAG-BAP1 for 48 h and
H1650 cells were transfected with siBAP1 for 24 h
followed by Real-time PCR and IB assay. The expres-
sion levels of both mRNA and protein were elevated
after transfection in H1299 cells, yet suppressed in
H1650 cells, indicating high efficiency of obtaining
both siRNAs and recombinant plasmid (Fig. 6), as
expected.
We performed cell wound-healing and Transwell in
vitro cell invasion assay to investigate the functional
role of BAP1. H1299 cells were transfected with
p3xFLAG-BAP1 plasmid and H1650 cells were trans-
fected with siBAP1. After 48 h, the cells were either
subjected to the wound-healing assay or to the Trans-
well invasion assay. Cellular migration ability of
H1299 was potently attenuated by BAP1 overexpres-
sion, meanwhile, BAP1 gene expression silencing in
H1650 cells resulted in a remarkably faster wound
healing process compared with the controls (Fig. 7).
The Transwell invasion assay also showed that over-
expression of BAP1 was accompanied with signifi-
cantly attenuated cellular invasive ability in H1299,
which, conversely, was enhanced in H1650 cells by si-
lencing of siBAP1 (Fig. 8). Finally, to elucidate the
mechanism by which BAP1 suppresses invasion and
metastasis in LAC cells, we analyzed the expression
levels of metastasis-related proteins in transfected
H1299 cells and H1650 cells using IB, respectively. We
observed a significant reduction of MMP-2 and Vimen-
tin, as well as apparent increasing of E-Cadherin. One
may therefore speculate that BAP1 affects the expres-
sion of metastasis-related proteins in these lines, which,
in vivo, has the potential to influence the metastatic
capability of LAC cells (Fig. 9).
BAP1 promotes cell death and suppresses cell
proliferation in LAC
To address whether BAP1 also regulates cell death both
by apoptosis and necrosis, we conducted a cell apoptosis
assay in LAC cells. H1650 and H1299 cells, transfected
with or without siBAP1 or BAP1 plasmid were incu-
bated with doxorubicin for 16 h, before analysis by flow
cytometry (FACS). Dual parametric dot plots combining
Annexin-V and PI fluorescence show four quadrants,
among which the lower left quadrant represented total
viable cell population (Annexin-V−/PI−), the lower right
represented the early stage apoptotic cell population
(Annexin-V+/PI−), and the late necrotic and late apop-
totic cells would cluster in the upper right-hand
Fig. 9 Synchronous detection of BAP1 expression and EMT proteins. The amount of vimentin varied in accordance with BAP1 while both MMP2
and E-Cadherin were inversely modulated with BAP1 expression
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Fig. 10 BAP1-mediated cell death displays properties of both apoptosis and necrosis. a Lung adenocarcinoma cells in early apoptosis (G4) were
detected by flow cytometry. b Bar chart showing the percentage of early apoptosis cells
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quadrant (Annexin-V+/PI+). We observed that overex-
pression of BAP1 gave rise to a sharp increase in early
stage apoptotic population up to 13.45 % and a slight in-
crease in late-stage apoptotic/necrotic cells up to 5.81 %,
which was significantly higher than the control group
(5.51 % apoptosis, p < 0.05; 4.11 % necrosis, p < 0.05).
Conversely, silencing BAP1 expression reduced the early
stage apoptotic cell population to 2.71 %, significantly
lower than that of the control (5.25 %, p < 0.05), suggest-
ing that BAP1 promotes tumor cell death by apoptosis
and necrosis (Fig. 10). A set of cell proliferation assays
was therefore performed to elucidate whether BAP1
also plays an essential role regulating cell prolifera-
tion. H1299 cells were transfected with BAP1 plas-
mid and H1650 with siBAP1 followed by treatment
with CCK-8. The intersection point of the prolifera-
tion curves of siBAP1 H1650 cells and the control
group was seen at 48 h, while the growth of BAP1-
overexpressing H1299 cells almost overlapped that of
the controls. The latter observations suggest that
BAP1 has little effect on cell proliferation in LAC
(Fig. 11).
Discussion and conclusions
Study of BAP1 expression in malignant and benign lung
tissues provides novel insights into the role of this pro-
tein in LAC. As a newly identified biomarker, BAP1 is
highly expressed in non-neoplastic lung tissues and re-
versely correlated with tumor invasion and node metas-
tasis. Moreover, BAP1 predicts longer survival in
patients with LAC. Functionally, BAP1 promotes apop-
tosis and necrosis, and down-regulates the migration
and invasion abilities of LAC cells. Thus we confirm that
BAP1 serves as a cancer precursor as well as a powerful
predictor of improved outcome and reduced likelihood
of recurrence.
In the present study, we observed that BAP1 expres-
sion was significantly less frequent in LAC tissue
(28.6 %) than in non-neoplastic lung diseases (90.1 %;
Fig. 3; Table 2). This suggests that BAP1 might suppress
initial lung tumorigenesis through an unknown mechan-
ism, implying that further experiments on the role of
BAP1 in cell apoptosis are required. We subsequently
observed that BAP1-mediated cell death displays fea-
tures implicating both apoptosis and necrosis. Thus,
BAP1 might suppress tumorigenesis by facilitating
tumor cell death by activation of both these pathways.
Our immunohistochemical and clinical investigations
demonstrated that BAP1 expression was inversely corre-
lated with pathologic TNM stage, node status, pleural
invasion, rate of relapse and metastasis. According to
the TNM classification for lung cancer of 2009, T stage
depends on a range of factors including the maximum
diameter of the tumor, pleural invasion, distant to the
carina, atelectasis or obstructive pneumonitis, nerve in-
vasion and separate tumor nodule(s) [18]. However, a
small proportion of cases present with the following
characteristics: (a) tumor in the main airway, less than
2 cm from the carina (none in the present study); (b)
tumor accompanied by pneumonitis (3 cases); (c) separ-
ate tumor nodule(s) (5 cases). In these cases, tumor size
as well as pleural invasion determine T stage to a large
degree. Considering that BAP1 expression is not associ-
ated with tumor size (p = 0.849) but inversely correlated
with pleural invasion (p = 0.004) (Table 3), it is reason-
able to believe that pleural invasion had the greatest
contribution. It is widely accepted that metastasis is a
major hallmark of malignancy and cancer cell invasion is
one of the essential early events in metastasis. BAP1
may inhibit the progression of LAC by attenuating
tumor invasiveness, a function that was supported by
the findings of the Transwell assay (Fig. 8). However,
BAP1 is closely related to lymph node status (Table 3),
suggesting that BAP1 also mediates suppression of cell
migration in LAC which is in keeping with the findings
of the wound-healing assay (Fig. 7).
The secretion of proteases such as matrix metallopro-
teinases (MMPs), capable of degrading the extracellular
matrix (ECM) to create space through which cells can
migrate, is also modulated by BAP1 expression.
Fig. 11 Correlation between BAP1 expression and cell proliferation expressed as cell proliferation curves
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Specifically, overexpression of certain MMPs, including
MMP2, is directly involved in the progression, invasion
and metastasis of LAC [19–21]. E-Cadherin plays an
essential role in the maintenance of the normal struc-
ture and adhesion of cells and its deregulation is asso-
ciated with tumor invasion and metastasis, being
reduced or absent in a vast majority of NSCLC cases
[22–24]. Other tumor metastasis-associated proteins,
Vimentin for example, are also down-regulated fol-
lowing the silencing of BAP1 [25]. According to the
above results, we postulate that BAP1 may regulate
these proteins and impact on tumorigenesis, inhibiting
invasion and local metastasis.
Previous research has shown BAP1 to be an independ-
ent prognostic factor in colorectal carcinoma [26] and
renal-cell carcinoma [27, 28]. This study reveals for the
first time that BAP1 is associated with post-operation
survival time of LAC, predicting longer OS and DFS.
Further prospective studies of large cohorts are neces-
sary to confirm the potential value of BAP1 in predicting
the outcome of LAC patients before being put it into
clinical practice.
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